Attenuated, replication-competent, oncolytic herpes simplex virus type 1 (HSV-1) are effective at infecting and lysing many human malignancies in preclinical studies. Nectin-1 is a cell-surface receptor for HSV-1 envelope glycoprotein D (gD) that also forms a component of intercellular adherens junctions (AJs). We sought to determine if the disruption of AJs in squamous cell carcinoma (SCC) through calcium depletion could be utilized to increase nectin-1 exposure and enhance HSV therapy. NV1023 is a single copy g 1 34.5-deleted, lacZ-expressing, oncolytic HSV-1. Calcium depletion caused cell separation and increased nectin-1 expression for three SCC cell lines growing at confluence. NV1023 viral entry, soluble gD protein binding and NV1023 cytotoxicity were all significantly enhanced for these cell lines at low calcium conditions. The increase in NV1023 entry at low calcium conditions was abrogated by nectin-1 antibody blockade. Murine SCC flank tumors treated with ethylenediaminetetraacetic acid (EDTA) showed increased nectin-1 expression and increased susceptibility to NV1023 infection. Combined NV1023 and EDTA intratumoral injections demonstrated significantly enhanced tumor regression as compared to NV1023 alone. These findings establish, as proof-of-principle, that herpes viral receptor expression may be modulated on cancer cells to enhance oncolytic therapy. This strategy might have future application toward improving therapy with a variety of herpes vectors.
Introduction
Attenuated, replication-competent viruses based on herpes simplex virus type 1 (HSV-1) have an ability to infect and lyse a wide variety of malignant tumors, making them attractive as potential therapeutic agents. [1] [2] [3] [4] [5] [6] [7] [8] Several early clinical trials have suggested that attenuated herpes viruses may be safe for clinical application.
9-11 Our group described the construction of a series of replicationcompetent, attenuated viruses (NV1020 series) based on HSV-1 that have demonstrated selectivity and efficacy in treating human cancers in animal models. [12] [13] [14] [15] Effective herpes oncolysis is dependent on successful initial viral entry into a host cancer cell. HSV-1 interactions with cell membranes are mediated principally by five herpes envelope glycoproteins (gB, gC, gD, gH and gL). 16 An HSV-1 viral particle initially binds to a cell's surface by interactions between viral gB or gC and cell membrane heparin sulfate and chondroitin sulfate proteoglycans. HSV gD then attaches to one of three receptors that are necessary for initiation of fusion of the viral envelope with the cell membrane. These receptors include nectin-1, herpes virus entry mediator (HVEM) and heparan sulfate modified by 3-O-sulfotransferase. HSV gD interactions with these receptors trigger viral gH and gL to form a complex that mediates fusion between the viral envelope and the cell membrane, allowing viral entry to occur. 16 The number of nectin-1 and HVEM receptors present on a cell membrane surface correlates with susceptibility to herpes viral entry. 17, 18 Our group recently demonstrated that the nectin-1 level of expression by squamous cell carcinoma (SCC) is strongly correlated with its sensitivity to viral entry and oncolysis by an attenuated, replication-competent, oncolytic herpes virus (NV1023). 18 These studies prompted our investigation into identifying potential methods of enhancing nectin-1 on target cancer cells.
In addition to its role as an HSV-1 receptor, nectin-1 is a cell adhesion molecule that forms an important component of intercellular adherens junctions (AJs). AJs are composed of transmembrane interactions between nectin-1 and E-cadherin, and mediate cell-cell adhesion in association with tight junctions and desmosomes.
Interestingly, the calcium-mediated disruption of AJs between Madin-Darby canine kidney cells has been shown to be able to liberate nectin-1 that is normally confined within intact AJs and inaccessible to viral particles. 20 Liberated nectin-1, is able serve as a functional receptor for HSV-1 entry. Our goal was to determine whether this concept could be applied to enhance herpes viral infection of cancer in the application of oncolytic herpes viruses. We sought to determine if calcium depletion could (1) disrupt cancer cell intercellular adhesion, (2) enhance nectin-1 on cancer cells, (3) increase oncolytic HSV entry into cancer cells and (4) enhance HSV oncolysis in vitro and in vivo.
Materials and methods

Cell lines
Five human head and neck SCC cell lines were studied: SCC15, SCC25, MSKQLL1, MDA1386 and H922. All cell lines were grown in minimal essential medium (MEM) containing 10% fetal calf serum (FCS) and 1% P&S.
Virus
We described the construction of NV1023, an attenuated, replication-competent, oncolytic herpes virus.
16 NV1023 was derived from R7020, an HSV-1 originally designed as a vaccine candidate.
3,21 NV1023 carries a 5.2 kb fragment of HSV-2 DNA, containing HSV-2 genes US2-2 to US2-5, inserted in the UL/S junction. 16 NV1023 is attenuated by a 15 kb deletion in the inverted repeat region that extends from the 3 0 -end of UL55 to the promoter for ICP4, deleting UL56 and one copy of the diploid genes ICP0, ICP4 and g 1 34.5. NV1023 also contains the Escherichia coli b-galactosidase gene inserted at the US10-12 locus under control of the a47 promoter and expresses wild-type HSV-1 envelope glycoproteins. NV1023 was provided by MediGene Inc., San Diego, CA.
Normal and low calcium conditions Low calcium conditions were defined as MEM without any added calcium with 10% FCS subjected to calcium chelation by passage through Chelex-100 (Bio-Rad, Hercules, CA) with 1% P&S. Normal calcium conditions are defined as MEM containing 10% FCS and 1% P&S.
Nectin-1 immunofluorescence
Cells incubated in normal or low calcium media for 30 min were fixed in methanol, blocked with 1% bovine serum albumin and incubated with a polyclonal, goat, anti-nectin-1 primary antibody (1:200, Santa Cruz Biotechnology, Santa Cruz, CA). Cells were washed and then incubated with a green fluorescent, rabbit, anti-goat IgG antibody (1:500, Alexa Fluor 488, Invitrogen, Carlsbad, CA). Slides were stained with 4 0 ,6-diamidino-2-phenylindole (5 mg/ml) and examined by confocal microscopy.
Viral entry assays
Cells were plated in 96-well plates in 100 ml of normal or low calcium media for 30 min and were then exposed to NV1023 at multiplicity of infection (MOI) 0, 0.1, 1 or 5. After 1 h incubation, all wells were washed and replaced with normal media. After 9 h, NV1023 entry as measured by lacZ assay was assessed using an Enhanced bGalactosidase Assay Kit (Gene Therapy Systems, San Diego, CA) and spectrophotometry. Substrate was added and plates were read on a spectrophotometer at 570 nm. Results are measured as optical density7s.e.m.
Receptor blocking assays
The viral entry assay was modified for receptor blocking assays. Cells were plated in 96-well plates in normal or low calcium media as described above and were then chilled on ice. Mouse monoclonal antibodies CW10 (anti-HVEM) and R1.302.12 (anti-nectin-1) were serially diluted to 0.01, 0.1, 1, 10 and 100 mg/ml in 50 ml media. An equal volume of NV1023 virus diluted in culture medium to a dose of MOI 5 was added and cells were incubated at 371C for 6 h. b-Galactosidase activity was then measured using lacZ assays as described above. Data are expressed as the percentage of viral entry under antibody blockade as compared to under unblocked conditions.
Cytotoxicity assays
Cancer cells (2 Â 10 4 ) were plated in 12-well plates and incubated in normal or low calcium media for 1 h. NV1023 was then added at MOI 5 or 0. After 6 h of incubation, an equal volume of MEM with double (or normal) added calcium and 10% FCS was added to low (or normal) calcium wells to normalize calcium conditions. For QLL1 cells, the length of calcium depletion was varied. After 72 h, cells were washed with phosphate-buffered saline (PBS) and lysed with Triton X (1.35%). Released lactate dehydrogenase was quantified using a Cytotox 96 kit (Promega, Madison, WI) and spectrophotometry (EL321e, Bio-Tek Instruments, Winooski, VT) at 450 nm. Control wells not exposed to NV1023 were considered to be 100% viable. Results are expressed as the percentage of surviving cells7s.e.m. Results were expressed as the percentage of surviving cells determined from comparing virally treated samples to non-virally treated samples.
Soluble gD:Fc fusion protein cellular ELISA Plasmid for a gD:Fc soluble fusion protein (Dr Patricia Spear, Northwestern University) was used to transfect CHO-K1 cells using lipofectamine (Invitrogen). Supernatant was collected at 48 h, clarified by centrifugation and gD:Fc protein quantified using an anti-rabbit IgG ELISA kit (Alpha Diagnostic, San Antonio, TX). Cells in 96-well plates were incubated at normal or low calcium conditions for 30 min and then fixed with 2% formaldehyde and 0.2% glutaraldehyde, and incubated with 50 ml of gD:Fc protein (1 mg/ml) for 1 h at room temperature (RT). Cells were washed and exposed to a biotinylated, anti-rabbit IgG secondary antibody (1:1000, Chemicon, Temcula, CA) for 30 min at RT, followed by streptavidinconjugated horseradish peroxidase (1:20 000, Amersham Biosciences, Piscataway, NJ) for 30 min. Substrate (3, 3 0 ,5,5 0 -tetramethylbenzidine) with sodium perborate was added (T-5525, P4922, Sigma-Aldrich, St Louis, MO) and plates were read on a spectrophotometer at 370 nm. Results are reported as optical density7s.e.m.
Murine flank tumor therapy
Flank tumors were established for the MSKQLL1 cell line by injecting 2 Â 10 6 tumor cells in 50 ml of PBS into the subcutaneous flanks of athymic nude mice (National Cancer Institute, Frederick, MD) anesthetized with inhalational methoxyfluorane. Animals were distributed into four experimental groups (n ¼ 7 per group) with equitable starting tumor volumes. Flank tumors were treated by a single intratumoral injection (100 ml) of (1) saline as a control, (2) 0.25% EDTA, (3) NV1023 (2 Â 10 7 plaque forming unit (PFU)) in PBS or (4) NV1023 (2 Â 10 7 PFU) in 0.25% EDTA. Tumor dimensions were serially measured and tumor volumes calculated by the formula for the volume of an ellipsoid: volume ¼ (4/3) Â p Â (length/2) Â (width/2).
2 Animals were monitored for any signs of toxicity or morbidity associated with either NV1023 or EDTA administration. Photographs were taken of representative animals at day 12.
Nectin-1 immunohistochemistry
Established MSKQLL1 flank tumors were injected with 100 ml EDTA or 100 ml PBS. Animals were killed after 30 min, and flank tumors were excised, frozen in Tissue Tek solution and cut into sections 8 mm thick. Slides were fixed with 2% formaldehyde and 0.2% glutaraldehyde, quenched with 1% hydrogen peroxide, incubated with 1.5% blocking serum and incubated with nectin-1 polyclonal antibody (1:200, Santa Cruz Biotechnology) overnight at 41C. Slides were incubated with a biotinylated secondary antibody, and visualized with an avidin-biotin complex kit (ABC Staining System, Santa Cruz Biotechnology). Slides were counterstained with hematoxylin, dehydrated in ethanol and histoclear, and mounted.
X-gal histochemistry
Established flank tumors of MSKQLL1 were injected with NV1023 (2 Â 10 7 PFU) in either 100 ml EDTA or PBS. After 24 h, animals were killed, and flank tumors were excised, frozen in Tissue Tek solution and cut into sections 8 mm thick. Slides were fixed with 1% glutaraldehyde for 5 min, washed with PBS and stained with X-gal (1 mg/ml) in an iron solution of 5 mM K 4 Fe (CN) 6 , 5 mM K 3 Fe (CN) 6 and 2 mM MgCl 2 at 371C for 2 h. Slides were counterstained with nuclear fast red.
Results
Cell-cell adhesion
A panel of squamous carcinoma cell lines was studied under normal and low calcium media conditions to assess for changes in intercellular adhesion characteristics by microscopy. When incubated in normal media, three cancer cell lines (QLL1, SCC15 and SCC25) were observed to grow in a tightly packed, dense pattern with complete coverage of the plate and no intercellular spaces visible at maximal confluence ( Figure 1a) . Two other cancer cell lines (1386 and H922) grew in normal media in a loose pattern, with less cell-cell contact and with sizable intercellular gaps (Figure 1a) . At maximum confluence, these cells began to detach and die, with intercellular gaps remaining between cells. QLL1, SCC15 and SCC25 therefore demonstrated greater baseline cell-cell adhesion than 1386 and H922 at normal media conditions.
These five SCC cell lines were incubated under low calcium conditions using MEM without any added calcium and 10% FCS that had undergone calcium chelation. The QLL1, SCC15 and SCC25 cell lines developed small intercellular gaps, reflecting calcium-mediated disruption of intercellular AJs. Under phase contrast microscopy, the borders between adjacent cells become more sharply defined as and the cells began to separate and assume a more rounded shape (Figure 1a ) after 30 min of exposure to low calcium media. In contrast, the 1386 and H922 cells, which did not exhibit significant cell-cell contact at maximum confluence, did not demonstrate morphologic changes in low calcium media. These observations suggest that low calcium conditions may induce cell separation of the SCC cell lines with strong intercellular adhesion characteristics, but not in the SCC cell lines that grow loosely in a non-confluent pattern.
Nectin-1 immunofluorescence
The cell-surface expression of nectin-1 on squamous carcinoma was assessed in normal and low calcium media by immunofluorescence microscopy. A polyclonal, antinectin-1, primary antibody followed by a secondary green fluorescent antibody was used. The QLL1, SCC15 and SCC25 cell lines demonstrate significant enhancement of cell-surface nectin-1 expression after 30 min of exposure to low calcium media as compared to normal media (Figure 1b) . In contrast, there were no visible changes in nectin-1 expression for the 1386 and H922 cell lines in low calcium media as compared to normal media. These findings suggest that cell-surface nectin-1 may be more accessible for antibody binding under low calcium conditions. Viral entry assays Viral entry assays were performed to determine whether increased cell-surface nectin-1 under low calcium conditions could act functionally as a receptor for an oncolytic HSV-1. NV1023 is an attenuated, replication-competent, single copy g 1 34.5-deleted HSV-1 that expresses bgalactosidase. Viral entry was assessed by lacZ assay 9 h after exposure of cells to NV1023 at an MOI of 0, 0.1, 1 or 5 in either normal or low calcium media. At MOI 5, viral entry was significantly enhanced for QLL1, SCC15 and SCC25 in low calcium media as compared to normal media (Po0.05 for all comparisons, t-test, Figure 2a) . The relative percentage of NV1023 viral entry under low calcium conditions as compared to normal conditions was 192% for QLL1, 134% for SCC15 and 177% for SCC25 after adjusting for background.
The relative increases in NV1023 viral entry at low calcium conditions were consistent with visual changes in Calcium depletion enhances oncolytic HSV therapy Z Yu et al nectin-1 immunofluorescence (Figure 1b) . Both QLL1 and SCC25 appeared to have larger increases in surface nectin-1 by immunofluorescence. SCC15 exhibited higher baseline nectin-1 expression in normal media, and therefore exhibited a smaller relative increase in both nectin-1 expression and NV023 viral entry in low calcium media. There were no significant differences in NV1023 viral entry into the 1386 or H922 cell lines in low calcium media as compared to normal media (Figure 2b ).
gD:Fc cellular ELISA
The SCC15 and SCC25 cell lines were selected to test if the increase in viral entry in low calcium media was mediated through a mechanism of altered HSV envelope gD binding to cell-surface gD receptors. We used a soluble gD:Fc fusion protein (Dr Patricia Spear) to perform cellular ELISA on the SCC15 and SCC25 cell lines under normal and low calcium conditions. Cell surface binding was detected with cellular ELISA using a Figure 1 (a) SCC growth patterns and intercellular adhesion at normal and low calcium conditions. Three cancer cell lines (QLL1, SCC15 and SCC25) grow in a crowded pattern with dense cell-cell contact at confluence in normal media as seen by phase contrast microscopy. After 30 min exposure to low calcium media, junctions between these cells become more sharply defined and cells begin to dissociate, showing early disruption of intercellular adhesion. In contrast, two other cancer cell lines (1386 and H922) grow with gaps between cells in a loose pattern even at maximal confluence, and show less intercellular adhesion. Under low calcium conditions, these cell lines do not show a change in morphology.
(b) Immunofluorescence for nectin-1 at normal and low calcium conditions. The three cell lines growing in a densely crowded pattern (QLL1, SCC15 and SCC25) with high intercellular adhesion show significant increases in nectin-1 expression at low calcium conditions. In contrast, the two cell lines growing in a loose pattern (1386 and H922) with low intercellular adhesion did not demonstrate changes in nectin-1 expression at low calcium conditions.
Calcium depletion enhances oncolytic HSV therapy Z Yu et al biotinylated secondary antibody directed against the Fc portion of the fusion protein. At the highest concentration of gD:Fc protein tested (10 mg/ml), there were significant increases in gD binding for both SCC15 (126%) and SCC25 (130%) in low calcium media as compared to normal media (Po0.05, t-test, Figure 3a) . At progressively lower concentrations of gD:Fc protein, these differences gradually diminished. These findings demonstrate that exposure to low calcium media allows for enhanced soluble gD protein binding to SCC15 and SCC25 cell surfaces.
Nectin-1 antibody blockade of viral entry
To further define the role of nectin-1 in mediating NV1023 entry under low calcium conditions, we performed nectin-1 antibody blockade studies using the QLL1 cell line. QLL1 supports increased NV1023 entry at low calcium conditions, but expresses relatively low NV1023 viral entry at normal and low calcium conditions. Viral entry as measured by lacZ assays was significantly enhanced at MOI 5 after 30 min of exposure to low calcium media as compared with normal media (Po0.05, t-test) for cancer cell lines with high baseline intercellular adhesion (QLL1, SCC15 and SCC25). In contrast, viral entry was unaffected at low calcium conditions (P ¼ NS) for cell lines with low intercellular adhesion (1386 and H922).
Calcium depletion enhances oncolytic HSV therapy Z Yu et al amounts of nectin-1 at a baseline state. Increasing concentrations of an anti-human, nectin-1 polyclonal antibody were used to block QLL1 cell-surface nectin-1 receptors, and NV1023 viral entry was then assessed at both normal and low calcium conditions. High concentrations of nectin-1 antibody were able to abolish the increase in NV1023 viral entry seen in low calcium media (Figure 3b ). In contrast, under normal calcium conditions, there was no significant change in NV1023 entry with nectin-1 blockade, suggesting that nectin-1 may not play a central role in supporting HSV entry for QLL1 under normal media conditions. Alternate gD receptors such as HVEM or HS-3-OST may permit HSV entry. This finding is consistent with immunofluorescence results showing low baseline levels of nectin-1 on QLL1 cell surfaces at normal calcium conditions. As a comparison study, nectin-1 antibody blockade was also performed on the 1386 cell line, which did not show any change in nectin-1 expression or NV1023 viral entry in low calcium media. NV1023 viral entry of 1386 was reduced under both normal and low calcium conditions to a similar degree with nectin-1 antibody blockade. These data confirm that nectin-1-mediated viral entry is not increased at low calcium conditions for 1386, in contrast to QLL1.
Cytotoxicity assays
We sought to determine if our observed increase in NV1023 viral entry under low calcium conditions would translate to an increase in cancer cell death from oncolysis, which is the therapeutic end point of interest. NV1023 was added to each of the five cancer cell lines in normal or low calcium media at MOI 5, and compared to control wells without virus. We noted that under continuous and prolonged low calcium conditions, cells tended to appear unhealthy, propagate poorly and failed to strongly support viral replication (data not shown). To make the calcium depletion transient, samples were exposed to NV1023 in normal or low calcium media for 6 h, and then low calcium wells underwent calcium replacement by adding an equal volume of MEM with double calcium concentration with 10% FCS. Percentage of cell viability was then measured by performing lactate dehydrogenase (LDH) assays at day 3. LDH levels of wells without viral treatment were used to represent 100% viability.
Under these transient low calcium conditions, QLL1, SCC15 and SCC25 all showed significant enhancement of NV1023 cytotoxicity as compared to normal conditions ( Figure 3 ). QLL1 showed an additional 36% increase in cell death by NV1023 at low calcium conditions as Figure 4 NV1023 viral cytotoxicity at normal and low calcium conditions. There is a significant enhancement of NV1023 cytotoxicity for the cancer cell lines with strong intercellular adhesion (QLL1, SCC15 and SCC25) at low calcium conditions as compared to normal calcium conditions (Po0.05 for all three comparisons, t-test). The time course of calcium depletion for QLL1 suggests that longer time periods of exposure to low calcium conditions do not lead to additional enhancement in NV1023 cytotoxicity. The cell lines lacking intercellular adhesion (1386 and H922) failed to demonstrate any significant alteration in NV1023 cytotoxicity at low calcium conditions (P ¼ NS for both comparisons). To facilitate comparisons with normal media conditions, the viability of cells at low calcium conditions is also presented after normalization of the non-virus-treated samples to 100% viable (adjusted columns).
Calcium depletion enhances oncolytic HSV therapy Z Yu et al
Continuous low calcium exposure detracted from cytotoxic effects (data not shown). Both 1386 and H922 failed to show any significant enhancement in NV1023 cytotoxicity at low calcium conditions. Calcium depletion in the absence of virus did not alter of cell viability for QLL1, SCC15, SCC25 or H922. Only 1386 showed a mild decrease in cell viability under low calcium conditions.
Murine flank tumor therapy MSKQLL1 flank tumors were established in athymic nude mice. A 100 ml intratumoral injection of EDTA (0.25%) led to increased tumor nectin-1 staining by immunohistochemistry as compared to saline-injected controls. Intratumoral injections of NV1023 (2 Â 10 7 PFU) in EDTA (0.25%) showed enhanced lacZ staining as compared with NV1023 alone ( Figure 5 ). Established MSKQLL1 flank tumors were then treated with a single intratumoral injection of (1) saline, (2) EDTA (0.25%), (3) NV1023 (2 10 7 PFU) or (4) NV1023 þ EDTA (n ¼ 7 per group). At day 12 after treatment, flank tumor volumes were found to be significantly lower for the NV1023 þ EDTA group (1376 mm 3 ) in comparison to the NV1023 alone group (41719 mm 3 , Po0.05, Figure 6 ). EDTA alone resulted in only a small reduction in tumor volume (118738 mm 3 ) as compared to saline-treated control flank tumors (148745 mm 3 , P ¼ nonsignificant (NS)). Tumors injected with EDTA formed small, localized hematomas at the injection site, which resolved over several days. There were no other toxicities observed that were associated with either EDTA or NV1023 injections.
Discussion
Herpes oncolytic viruses have shown promising activity against a variety of human malignancies. However, there is variation in the level of susceptibility of cancers to herpes viruses, and this variation is particularly evident at low viral doses. 7, 8 We recently demonstrated that the degree of nectin-1 expression by a cancer cell line correlates strongly with its susceptibility to NV1023 viral entry and oncolysis in vitro.
18 Furthermore, tumors with high nectin-1 levels demonstrated better regression in vivo in comparison to those with low nectin-1 levels following intratumoral injection of NV1023.
These findings suggest that NV1023 entry into cancer cells through nectin-1 receptors is an important step for effective oncolytic therapy, and prompted our investigation into potential methods of increasing nectin-1 availability on cancer cells. Yoon and Spear 20 showed that nectin-1 on Madin-Darby canine kidney cells normally engaged in AJs between cells can be liberated to serve as functional herpes viral receptors following the disruption of AJs with extracellular calcium depletion. We tested whether this concept could be applied toward the therapeutic application of an attenuated, oncolytic herpes virus in the treatment of SCC.
We found that herpes viral oncolysis may be enhanced by the modulation of extracellular calcium levels and nectin-1 expression in certain SCCs. For cancer cell lines growing in loose patterns with weak intercellular adhesion in vitro, calcium depletion did not alter nectin-1 exposure and did not affect HSV entry. This finding is understandable, as in the absence of intact AJs at baseline we would not expect a change in nectin-1 with calcium depletion. However, for cancer cell lines growing in a tightly packed, dense pattern with extensive cell-cell contact in vitro, extracellular calcium depletion led to (1) the disruption of intercellular adhesion, (2) enhancement of cell-surface nectin-1, (3) increased gD binding and NV1023 viral entry, and (4) increased NV1023 cytotoxicity. For these cell lines, low calcium conditions liberated nectin-1, which served as a functional receptor for oncolytic herpes viral entry. The relative magnitude of increase in viral sensitivity at low calcium conditions is likely related to the amount of liberated nectin-1 derived from AJ disruption as compared to the cell line's baseline levels of accessable nectin-1.
In a murine flank tumor model of MSKQLL1, intratumoral injections of a calcium chelator (EDTA) resulted in increased tumor nectin-1 expression and NV1023 viral entry in vivo. EDTA significantly enhanced NV1023 therapy as compared to NV1023 alone. The addition of a calcium chelator to the carrier solutions for herpes oncolytic viruses appears to be a simple method of applying this strategy to enhance HSV therapy in vivo.
As prolonged extracellular calcium chelation may actually impede herpes viral replication due to alterations in intracellular calcium physiology (data not shown), a single application of a calcium chelator with HSV in vivo is not only simple but may also be most efficacious. Our findings suggest that only a transient depletion of calcium is necessary to facilitate viral entry, a favorable finding as injected chelator would be cleared in vivo. Future studies investigating the duration of calcium depletion that is achievable in vivo and the potential application of other chelators such as ethylene glycol tetraacetic acid are warranted. Although we did observe small hematomas form at the tumor injection sites following EDTA administration, these were localized and quickly resolved. Animals did not exhibit any other morbidity attributable to either EDTA or NV1023 administration.
A strategy of combining herpes oncolysis with calcium chelation to enhance therapy may have important clinical application. For tumors with intact baseline AJs, localized calcium chelation may be a useful strategy to improve the degree viral entry and oncolysis. This strategy may also be applicable to enhancing viral transduction of other forms of gene therapy utilizing herpes envelope glycoproteins. Other therapies that may benefit from this strategy include the use of replicationdefective herpes viral amplicons and herpes DISC (defective infectious single cell cycle) viruses. These findings offer, as a proof-of-principle, the idea that the modulation of nectin-1 expression on cancer cells can be a potentially effective strategy for enhancing herpes viral gene therapy. These results also suggest that other agents capable of disrupting AJ integrity may also hold potential for enhancing oncolytic herpes therapy, and that such agents merit further investigation in this capacity.
